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AC  Anabolic charge 
AIH Autoimmune hepatitis 
ALP  Alkaline phosphatase 
ANA Anti-nuclear antibodies 
CI Confidence interval 
CTLA4 Cytotoxic T lymphocyte antigen 4 
EASL  The European Association for the Study of the Liver 
GPE Glyserophosphoethanolamine 
HILMO Hospital discharge registry 
HUH Helsinki University Hospital 
IAIHG The International Autoimmune Hepatitis Group 
ICD-10 International Classification of Diseases and Related Health Problems 
volume 10 
LFT  Liver function tests 
LKM Liver-kidney-microsome 
LT Liver transplantation 
MRI  Magnetic resonance imaging 
NA Not available 
NPV Negative predictive value  
NS  Statistically not significant 
OR Odds ratio 
pANCA Perinuclear anti-neutrophil cytoplasmic antibodies 
PBC Primary biliary cholangitis 
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PIC  Personal identity code 
PME Phosphomonoester 
31P MRS  31Phosphorus magnetic resonance spectroscopy 
PPV  Positive predictive value 
PSC Primary sclerosing cholangitis 
SII The Social Insurance Institution of Finland 
SLA  Soluble liver antigen 
SMA Smooth muscle antibodies 
SMR Standardised mortality ratio 
TE  Transient elastography (Fibroscan) 
TNF Tumour necrosis factor  
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Aims: This thesis includes one study (Study I) focused on epidemiological data 
regarding autoimmune hepatitis (AIH) and three studies (Studies II-IV) on follow-
up of AIH. The aims were to assess the incidence, prevalence, and causes of 
death in patients with AIH. Three other studies aimed to determine the role of 
follow-up liver biopsies in patient surveillance, to study non-invasive methods to 
quantify inflammation and fibrosis in AIH, and to evaluate the prognosis of 
patients with AIH after liver transplantation. 
Patients and methods: Patients with AIH code K73.2 or K75.4 with special 
reimbursement in the Social Insurance Institution of Finland registry were cross-
referenced with the data from the hospital discharge register to validate 
diagnoses. Five controls for all AIH patients were identified from Statistics 
Finland. Data from the Finnish cancer register were used to calculate 
standardized mortality ratios (Study I). All patients with AIH diagnosis in Helsinki 
University Hospital were included in the retrospective study of the impact of liver 
histology on disease progression, with special emphasis on follow-up biopsies 
(Study II). Twelve patients with AIH were investigated with magnetic resonance 
spectroscopy, liver biopsy, and transient elastography (Study III). Follow-up 
biopsies of all Finnish liver transplant recipients with AIH as an indication for 
transplantation were combined with clinical data to evaluate the prognosis and 
risk factors for AIH recurrence and graft loss (Study IV). 
Results: We showed that the median AIH incidence between 1995 and 2015 was 
1.0/100,000/year (1.2/100,000/year in women and 0.38/100,000/year in men) and 
increased from 0.28/100,000 to 1.0/100,000 during the study period. The 
prevalence of AIH in 2015 was 14/100,000, 23/100,000 in women and 
6.6/100,000 in men). The standardised mortality ratio was increased in all age 
groups and both genders. The most prevalent excessive causes of mortality when 
compared to the standard population were hepatocellular carcinoma, liver 
cirrhosis, and AIH per se (Study I). 
We identified the following prognostic variables for advancing fibrosis or cirrhosis 
in follow-up biopsies: interface or total inflammation, necrosis, cholestasis, or 
rosette formation in the baseline biopsy. If inflammation in the follow-up biopsies 
10 
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was constantly grade two or more in the Metavir scale, the hazard ratio (HR) for 
cirrhosis was 5.1, (95 % Confidence interval (CI) 1.6-16.2), p<.005). If interphase 
inflammation was constantly grade two or more, the HR was 6.1 (95 % CI 1.9-
20.2), p<.005. Only 7% of patients were cirrhotic at baseline. Fibrosis progressed 
in 42% of patients, remained stable in 39% and resolved in 18% (Study II). 
When compared to liver histology, magnetic resonance spectroscopy revealed 
distinctive ratios of selected hepatocyte metabolites in patients with advanced 
fibrosis or active inflammation in 12 consecutive AIH patients. Transient 
elastography was ineffective in fibrosis quantification (Study III). 
After liver transplantation, AIH recurred in 36% of patients; the median time until 
recurrence was 5 years (range 1.1-15 years). Recurrent AIH did not affect patient 
or graft survival. Patient and graft survival were 94% and 86% at 1 year, 86% and 
91% at 5 years, and 77% and 74% at 10 years, respectively. Immunosuppression 
without mycophenolate mofetil or azathioprine increased the risk of AIH 
recurrence. Recurrence was less common in patients without overlapping 
cholangitis (Study IV). 
Conclusions: The incidence and prevalence of AIH is similar in Finland as 
reported in other countries. Female preponderance is notable. We demonstrate 
that, especially in women, AIH occurs at all ages and often in the elderly. 
Hepatocellular carcinoma is rare but statistically is the most important cause of 
excess death. While liver biopsies might play a role in the follow-up of AIH, there 
are currently no good prognostic models that encompass liver histology. Ongoing 
histological inflammation is a risk factor for fibrosis progression and development 
of cirrhosis. Magnetic resonance imaging of the liver is a promising follow-up tool 
and is acceptable to patients. Transient elastography was not useful in this 
setting. AIH recurs after liver transplantation in 36% of patients but is of primarily 
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Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease, characterised 
by interface hepatitis on histologic examination, hypergammaglobulinemia and 
autoantibodies measured from the blood 1. The aetiology of autoimmune hepatitis 
is mostly unclear, but a triad of environmental triggers, failure in the immune 
tolerance and susceptibility due to genetic factors, induce a T-cell mediated 
immune attack against liver antigens leading to necroinflammatory hepatocyte 
damage and fibrosis generation 2,3. Although up to 25% of AIH present with an 
acute onset of disease 4, AIH is generally considered as a chronic disease in 
which inflammation leads to fibrosis and cirrhosis 5, and it seems that advanced 
liver disease per se is important for patient outcome 6-11. Studies on effective 
treatment options have been reported as early as in the 1970s and 1980s, and 
our treatment protocols are still based on these studies 12,13. The incidence and 
prevalence of AIH is estimated to be equal to primary biliary cholangitis and twice 
the amount of primary sclerosing cholangitis 5. Epidemiological data of AIH are 
scarce. Also, there are no epidemiological data of AIH in Finland. Clinical 
decisions regarding the treatment of AIH should be based on knowledge of the 
epidemiology and the prognosis of this disease. 
Liver histology is needed in AIH to establish diagnosis 14,15, and histological 
findings are known to be of prognostic importance 9,10,16-18. In Helsinki, we have 
taken routine follow-up liver biopsies and will determine their impact on treatment 
choices and prognosis. Furthermore, in HUS Medical Imaging Center, MRI 
spectroscopy with 3 Tesla imaging modality has been used in non-alcoholic fatty 
liver disease 19 to evaluate fibrosis and could also be used in AIH patients. 
Transient elastography (Fibroscan) is an ultrasound-based technic which 
assesses fibrosis in liver disease 20,21. Transient elastography can distinguish 
advanced fibrosis and cirrhosis from normal liver histology but does not reliably 
show mild fibrosis. It also plays no role in evaluation of inflammation. New non-
invasive tests in evaluation of inflammation and fibrosis are needed, and we 
hypothesise that MRI could be useful in this setting. In this study, liver histology 
served as the gold standard in determining the fibrosis stage and inflammation 
grade. 
12 
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AIH is a well-established indication for liver transplantation (LT) in cirrhotic 
patients with untreatable symptoms of portal hypertension, poor liver function or 
general symptoms 5. In Helsinki University Hospital (which performs and follows 
up all Finnish LT patients), we have a comprehensive registry of liver transplanted 
AIH patients. Their prognosis after transplantation was evaluated within this 
study. In addition, these patients undergo regular protocol liver biopsies after 
transplantation, and the reoccurrence of AIH after transplantation will be 
evaluated. During 1982-2008, of the 667 liver transplantations performed in 
Finland, 42 (6%) were done because of AIH 22.  
13 
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2 Review of the literature 
 
2.1 Epidemiology of AIH 
 
AIH is a rare and usually chronic liver disease. Incidence rates from 0.7 to 2.0 
100,000 person-years have been reported previously, depending on the 
population and data collecting method. The point prevalence rate has been 
reported from 8.0 to 43 per 100,000 person-years 7,23-30. There is variation 
regarding how the data is gathered in the studies, and only one of the previous 
studies included a complete nationwide registry 7. The highest prevalence rate of 
43 per 100,000 was reported in Alaska 26, whereas the prevalence in Southern 
Israel and Sweden were only 8.0 and 10.7 per 100,00024,30. In Alaska, patients 
also had a more severe presentation than what has been reported elsewhere 26.  
It has been speculated, that ethnic stability and background may play a role in the 
epidemiology of AIH, but the longest observation period published so far (from 
Denmark 1994-2012) 7, showed that the incidence of AIH nearly doubled from 
1.37 to 2.33 per 100,000 person-years. Incidence rose both in women and men. It 
remains to be seen whether this is due to improved diagnostics, or to a true 
increase in incidence. Altogether, this finding implies that the incidence has risen 
in a genetically quite stable population. 
The most stable finding in published studies is that AIH is more common in 
women. The women to men ratio in studies in general has been roughly three to 
one. The highest women to men ratio was reported in the Valencia district in 
Spain 28, with eighteen to one. Older studies have shown a bimodal distribution of 
incidence according to age, with peaks after puberty and around fifty years of age 
23,26,30-32. This finding has been challenged in more recent, and more 
comprehensive studies 7,29. It is important to recognise that AIH can occur in all 
ages and both genders. Results from previous epidemiological studies are 
illustrated in Table 1. 
14 
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TABLE 1. Incidence and prevalence rates of autoimmune hepatitis in selected 
registries, from Study I, with permission from Elsevier 
 
  Incidence Prevalence 
Location  /100,000 /100,000 Period Population Reference 
Oslo, Norway  1.9 16.9 1986-1995 130,000 23 
 
Canberra, Australia NA 8 NA 525,000 25 
 
Southern Israel  0.7 11.0 1995-2010 910,000 24 
 
Alaska  NA 42.9 1984-2000 100,312 26 
 
Denmark  1.7 23.9 1994–2012 5,600,000 7 
  Women 2.4 34.6   
  Men 0.9 13.0  
 
Valencia, Spain  0.8 11.6 1990-2003 112,003 33 
  Women 1.4 Women 19.2 
  Men 0.3 Men 3.7  
 
Valencia, Spain  1.1 NA 2003 1,774,736 28 
  Women 2.0 
  Men 0.1 
 
Canterbury,  2.0 24.5 2001-2008 494,170 27 
New Zealand               Women 35.3 
                    Men 13.2 
 
Sweden  0.9 10.7 1990-2003 715,000 30 
  Women 1.2 15  
  Men 0.5 6.2 
 
Amsterdam,  1.1 18.3 1967-2011 799,000 29 
The Netherlands 
 
NA, Not available 
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2.2 Aetiology and pathogenesis of AIH 
 
AIH may be a group of heterogenous diseases, with commonly agreed diagnostic 
criteria, Table 2 and 3. Diagnosis of AIH is based on the detection of 
autoantibodies, hypergammaglobulinemia, and chronic inflammation, preferably 
interface hepatitis, shown in the liver biopsy 34. The aetiology of AIH is complex 
and largely unknown. The current opinion is that in a genetically susceptible 
person, a triggering antigen can induce an unfavourable immune response and a 
break-down in immune tolerance 2,35-37. The triggering epitope is probably a short 
epitope in an infectious or toxic agent. Homology between this epitope and self-
antigens may stimulate a cross-reactive humoral and/or cellular immunological 
response, sensitising immunocytes to extend the immunological reaction beyond 
precise exoantigens. Immune environment in AIH patients is presumably 
favourable to prolonged and extended immune reactions and is thought to be 
different in different geographical regions and ethnic groups 5.  
Multiple triggering factors have been proposed: Viruses include hepatitis A 38, 
hepatitis B 39, hepatitis C 40, measles 41, and Epstein-Barr virus 42. Drugs that 
have been reported include nitrofurantoin 43, minocycline 44, atorvastatin 45, 
methyldopa and hydralazine 46. However, the lag time between a triggering agent 
and the onset of the clinical manifestations of the disease may be long, and 
usually a triggering agent cannot be identified, or there may not be one. 
AIH is a heterogenous disease. Altogether, genome-wide association study was 
performed in patients from the Netherlands and Germany in 2014 47. The study 
identified risk alleles in the major histocompatibility complex region and identified 
variants of SH2B3and CARD10 as likely risk factors. The conclusion of the 
authors was that the genetic basis for AIH is complex. It can be assumed that 
different genetic traits are risk factors or even causes for their own type of AIH, 
but in a large cohort in a heterogenous mixture of disease phenotypes, these 
genes fade out in the analysis. 
Molecular mimicry of a foreign and a self-antigen is a common hypothesis for loss 
of self-tolerance, but this mechanism has not been established in AIH 48. Genetic 
factors influence antigen presentation and CD4+ helper T cell recognition. In 
16 
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genetic studies, it has been shown that susceptibility alleles of AIH in Caucasians 
reside in the DRB1 gene in the class II major histocompatibility complex and are 
DRB1*0301 and DRB1*0401 1,49. Polymorphisms of the tumour necrosis factor 
(TNF) –α gene and cytotoxic T lymphocyte antigen 4 (CTLA4) gene 50 –have 
been identified in Caucasian AIH patients, and TNF-α is a known potent 
immunoactivator, as CTLA4 is a crucial regulator of self-tolerance. 
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2.3 Clinical spectrum and diagnosis of AIH 
 
The clinical spectrum of AIH is wide. Patients can be asymptomatic individuals 
with elevation of liver enzymes. On the other end of the spectrum is a fulminant 
life- threatening hepatitis. Patients can have symptoms due to hepatic or systemic 
inflammation, complications of cirrhosis, or even in extrahepatic organs, such as 
joints, skin, muscles or the gastrointestinal tract 5,51. 
Diagnosis of AIH is based on the detection of autoantibodies, 
hypergammaglobulinemia, and chronic inflammation, preferably interface 
hepatitis, shown in the liver biopsy 34. The International Autoimmune Hepatitis 
Group (IAIHG) have released their recommendations of diagnostic scoring in 
1999 (Revised scoring system for diagnosis of autoimmune hepatitis), which are 
suitable for clinical use, as well as investigational purposes, Table 2 14. Newer 
and simpler diagnostic criteria were published in 2008: Simplified scoring criteria 
for the diagnosis of autoimmune hepatitis 15 showed similar performance with 
fever parameters, Table 3. Both scoring systems have their advantages 52: 1999 
criteria have twelve parameters and are more sensitive, while 2008 has four 
parameters with better specificity and predictability. Also, 1999 criteria perform 
better in AIH with atypical features, and 2008 criteria are better in excluding 
patients with non-immune mediated liver diseases with nonspecific immunological 
alterations. There seems to be no difference in the validity of diagnosis or 
treatment response between probable and definite diagnosis, which concerns 
both diagnostic criteria 53. 
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Table 2.Revised scoring system for diagnosis of autoimmune hepatitis(adapted)14 
Variable Points 
Female sex +2 
  

















Anti-mitochondrial antibodies -4 
  
Viral hepatitis positive -3 
Viral hepatitis negative +3 
  
Drug history positive -4 
Drug history negative +1 
  
Alcohol <25 grams daily +2 
Alcohol >60 grams daily -2 
  
Interface hepatitis +3 
Lymphoplasmacytic infiltrate +1 
Rosettes +1 
None of the above -5 
Biliary changes -5 
Other changes -3 
  
Other autoimmune diseases +2 
  
Positive for other defined antibodies (optional) +2 
Human leucocyte antigen DR3 or DR4 (optional) +1 
  
Response to therapy +2 
Relapse after therapy withdrawal +3 
  
 Sum 
Pre-treatment definite AIH >15 
Pre-treatment probable AIH 10-15 
Post-treatment definite AIH  >17 
Post-treatment probable AIH 12-17 
19 
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Antinuclear or smooth muscle antibodies 1:40 1 
Antinuclear or smooth muscle antibodies ≥1:80 or 
Antibodies to liver-kidney microsome or 
Antibodies to soluble liver antigen 
2 
  
Immunoglobulin G > upper limit of normal 1 
Immunoglobulin G > 1.1 times upper limit of normal 2 
  
Compatible histology 1 
Typical histology 2 
  
Absence of viral hepatitis 2 
  
 Sum 
Definite diagnosis ≥7 
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2.4 Classification of AIH types 
 
Traditionally, AIH has been divided into types 1 and 2, Table 4. In 2000, a type 3 
AIH was proposed 54, however, some experts see type 3 AIH as a subtype of type 
1 autoimmune hepatitis51. Soluble liver antigen (SLA)-1 55 was shown to be 
present in the sera of patients with unknown inflammatory hepatitis. It has now 
been shown to be a strong predictor of relapse after treatment withdrawal 56. 
Some experts see this antigen as a marker of type 3 AIH 5, while some 
investigators see this as a variant of type 1 AIH. Some patients lack characteristic 
autoantibodies 57 even if they have an established AIH diagnosis. 
Type 1 is typically characterised by the expression of smooth muscle (SMA) 58 or 
anti-nuclear antibodies (ANA) 59, or both. Atypical perinuclear anti-neutrophil 
cytoplasmic antibodies (pANCA) 60 are present in as many as 96% of type 1 AIH 
patients but should be absent in type 2 patients. Type 2 patients are positive for 
the liver-kidney-microsome (LKM) antibody -161. It was first recognised in children 
aged 2-14 years old but has since been shown to also occur in adults 62. Target 
antigens in liver of type 1 patients are yet to be characterised, but LKM-1 in type 
two has a target antigen cytochrome P450 2D6 expressed in the liver 63. This 
antigen is also homologous to the hepatitis C genome, as well as the 
cytomegalovirus and herpes simplex virus, supporting the hypothesis that viral 
infections may be the cause of AIH 64. 
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Table 4. Traditional classification of AIH 
 
Feature Autoimmune hepatitis type 1 Autoimmune hepatitis type 2 
Autoantibodies Anti-nuclear, smooth-muscle, and 
perinuclear anti-neutrophil antibodies, 
and soluble liver antigen 
Liver-kidney microsomal 
antibody 
Age Any age Children and adolescents 
Association to HLA 
haplotypes 
DR3, DR4 DR3 
Clinical severity Variable Severe 
Treatment failure Uncommon Frequent 
Need for long-term 
maintenance 
therapy 




2.5 Accompanying cholangitis in patients with AIH 
 
Patients with primary biliary cholangitis (PBC) may have autoimmune hepatitis 65, 
as may patients with primary sclerosing cholangitis (PSC) 66, the latter known to 
be highly prevalent in children 67, and patients with inflammatory bowel disease 57. 
The 2011 position statement by The International Autoimmune Hepatitis Group 
(IAIHG) proposes that these patients should be categorised according to their 
predominant feature as AIH, PBC or PSC 68. That same paper also states that the 
number of patients with these formerly called overlap syndromes, is probably not 
sufficient enough to enable clinical studies. In our studies, we have decided to 
include patients who fulfil the Simplified criteria for the diagnosis of autoimmune 
hepatitis 15 and to report whether these patients had an accompanying 
autoimmune cholestatic disease. The transplantation rate was higher in children 
with AIH and PSC (87%) compared to pure AIH (77%)69. In adults, AIH+PSC 
patients had a transplantation free survival of 67% versus patients with pure AIH 
(92%)70. AIH+PBC has not been shown to affect patient survival, and they 




Autoimmune hepatitis: Epidemiology,                        Helsinki University Hospital 
prognosis and follow-up 
 
 
2.6 Treatment of AIH 
 
The European Association for the Study of the Liver clinical practice guidelines 
from 2015 (EASL) recommend all patients with AIH should be treated 71. The goal 
of the treatment is to treat symptoms of the liver disease and prevent progression 
of liver damage to cirrhosis by suppressing inflammatory activity. The American 
Association for the Study of the Liver Disease practice guidelines from 2010 
stated that symptomatic patients or patients with necrotic inflammation or high 
liver function tests should be treated, whereas in other patients the option to treat 
should be individualised 51. There is uncertainty regarding treating patients with 
only mild inflammatory activity since we have only one study which retrospectively 
compared untreated and treated patients with mild activity with no symptoms 72, 
and they only had follow-up data of eight patients with mixed results. They still 
showed that this patient population exists, and the total number of untreated 
patients was 21 (7%). 
The basis of treatment has been corticosteroids alone or in combination with 
azathioprine 73. Second line treatment options for corticosteroid or azathioprine 
intolerant patients include 6-mercaptopurine 74, mycophenolate mofetil 75, 
budesonide 76, of which budesonide is the only one tested in a randomised trial. 
Treatment options for steroid-refractory AIH include cyclosporine 77, tacrolimus 78, 
rituximab 79 and infliximab 80. These are included in the AASLD 51 guidelines but 
are based on case reports or case series. And if all this fails, liver transplantation 
is a viable option with a 74 percent 10-year patient and 85 percent graft survival 
22. 
 
2.7. Follow-up of AIH patients 
 
The ideal endpoint of initial therapy is normalisation of transaminases, 
immunoglobulin G, and resolution of tissue damage shown by liver biopsy, which 
is achievable in 90% of patients 51. Even in remission prior to therapy withdrawal, 
60% of patients still relapse 81. Liver biopsy prior to treatment tapering is 
essential, since up to 55% percent of patients with normal transaminases still 
23 
Autoimmune hepatitis: Epidemiology,                        Helsinki University Hospital 
prognosis and follow-up 
 
 
have interface inflammation in the liver 82, and these patients likely relapse after 
treatment discontinuation 51, even though this subject is poorly studied. Both 
EASL and AASLD recommend treatment tapering after two years of remission 
51,71. 
Follow-up imaging is not routinely necessary in AIH patients. Cirrhotic AIH 
patients have a 0.2% annual risk of developing hepatocellular carcinoma (HCC) 
83, and HCC surveillance is unlikely cost-effective until models to predict high risk 
HCC patients are developed. It is advisable that patients with elevated alkaline 
phosphatases during follow-up undergo cholangiography to detect possible 
associated cholangitis. 
31Phosphorus magnetic resonance spectroscopy (31P MRS) has been evaluated 
in hepatitis c and non-alcoholic fatty liver disease 19,84 and has shown promising 
results. 31P MRS can show both inflammation and fibrosis, which would be ideal 
in AIH follow-up. Anabolic charge (AC) is combination of elevated total 
phosphomonoester (PME) and decreased total phosphomonoester (PDE) in a 
fibrotic liver. Measuring anabolic charge can quantify fibrosis and separate 
patients with no or mild fibrosis from patients with advanced fibrosis 85,86. 
Phosphoethanolamine (PE) is a compound within the PME peak, and 
glyserophosphoethanolamine (GPE) is a part of PDE peak within the 31P MRS 
spectrum. Phosphoenolpyruvate (PEP) is a link in hepatic gluconeogenesis but its 
role in liver injury is unknown 87. Two 31P MRS spectra examples are illustrated in 
Figure 1.   
Transient elastography (TE) has been evaluated in AIH patients in two series 
comprising 28 patients but these series also included other liver diseases such as 
viral hepatitis. The authors reported only pooled results and showed that TE was 
able to reliably separate patients with a Metavir88 score <2 from a Metavir score ≥ 
2 patients 89,90. On the other hand, published case reports of AIH patients have 
shown disproportionally high TE results, presumably by ongoing inflammation 
20,91. In these cases, elasticity levels normalised after AIH treatment initiation.  
24 
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From Study III, with permission 92.  
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2.8 Prognosis of AIH patients 
 
The most significant predictor of poor outcome in AIH is cirrhosis at time of 
diagnosis. The presence of cirrhosis drops the 10-year survival from 94.0-94.4% 
to 61.9-61.7% 10,93. Bridging necrosis predicts the development of cirrhosis 16, but 
there is no direct evidence that necrosis itself leads to impaired prognosis. In a 
European population of 103 patients 94, where 29.1% of patients had cirrhosis at 
diagnosis, there was no statistical difference in prognosis between the groups 
with or without cirrhosis. In addition to a favourable outcome also in cirrhotic 
patients, cirrhotic patients seem to respond to treatment as positively as non-
cirrhotic patients 95. The impact of cirrhosis may also be mixed by the fact, that 
cirrhosis in AIH seems to be reversible 18: Nine out of fourteen patients showed 
resolution of cirrhosis in paired liver biopsies at diagnosis and after treatment 
initiation. Whether advanced fibrosis without cirrhosis affects survival, has not 
been studied. 
EASL and AASLD recommend histological follow-up during maintenance therapy 
to confirm treatment response, but there is no data to show how histological 
findings during follow-up influence the outcome 5,51. Liver biopsy is considered 
safe96. Complications (including pain) are extremely rare (0.06-0.32% of patients) 
and 0.009-0.12% people die.  
Most data that evaluate prognosis is focussed in baseline histology. Other, non-
histological variables have been proposed: Non-white ethnicity 97 and female sex 
98 have been shown to predict a poorer outcome, but these findings have not 
been confirmed in other studies. Not surprisingly, high liver function test levels 
and severe liver failure predict a poorer outcome 99. Recurrent relapses also 
reduce survival 81. 
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2.9. Liver transplantation due to autoimmune hepatitis 
 
Indications for liver transplantation (LT) due to autoimmune hepatitis (AIH) are 
identical to those with other liver diseases 100. The most important causes are 
acute or subacute liver failure, decompensated cirrhosis, and hepatocellular 
cancer. Short-term prognosis after LT is good, with 90% one-year survival and 
70% five-years survival 101, similar to alcoholic cirrhosis, but inferior to primary 
biliary cholangitis (PBC) 102. In the 2010 European Liver Transplantation registry 
data analysis, fatal infections occurred in the post-operative period at an 
increased rate in patients with AIH (HR 1.8, CI=1.2 2.6, p=.002 with PBC as the 
reference) 102, presumably due to the higher burden of immunosuppressive 
medication. The most worrisome finding in this report was that in AIH patients 
aged 50 or more, five-year survival was only 61% (confidence interval 51-70%). 
This should be taken into consideration in the pre-transplantation treatment of AIH 
patients, and it also highlights the importance of proper patient selection. 
Another typical feature of AIH as a LT indication is the high rate of recurrence in 
the graft (11% 40%) 103-105. Still, only 0.7% eventually die due to AIH recurrence 
106. A single centre report from the United Kingdom reported that overall graft loss 
was more frequent in AIH patients compared to PBC patients, HR 4.1 (95% CI 
1.3–12.6) for recurrent disease and 1.6 (95% CI 1.2–2.) for overall graft loss 107. 
Recipient HLA genotypes DR B1*0301 or DRB1*0401108, high or poorly controlled 
necroinflammatory disease activity in the explant liver109, and concomitant 
autoimmune diseases and high aminotransferase and immunoglobulin G levels 
prior to LT110,111 have been suggested as risk factors for AIH recurrence, but 
otherwise risk factors have been poorly defined. 
Acute rejection is more common in AIH patients than in LT patients in general 112. 
It also seems that chronic rejection is more common in AIH patients 113. On the 
other hand, there is no evidence that acute or chronic rejections lead to recurrent 
AIH development or vice versa.  
Immunosuppressive treatment after LT due to AIH is similar to 
immunosuppression in other LT patients. Cyclosporine and tacrolimus are equally 
effective in these patients 110. Rapid tapering of steroids is a risk factor for disease 
recurrence 109 and long-term corticosteroid therapy is safe and effective in these 
patients, resulting in a five-year AIH recurrence rate of 6% and a ten-year rate of 
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10% 114, Long-term corticosteroid use does not seem to result in excess 




Figure 2. Primary chronic liver diseases leading to LT in Finland from 1982 to 
October 2018 (Finnish transplantation registry)
 
NALFD, Non-alcoholic fatty liver disease; PBC, Primary biliary cholangitis;  
PSC, Primary sclerosing cholangitis  
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3 Aims of the Study 
 
The aims of the study are to 
Study epidemiology, prognosis and follow-up of AIH in Finland. 
 
1. Examine the epidemiology and causes of death of patients with 
autoimmune hepatitis in Finland. 
2. Find out the role of follow-up liver biopsies in patients’ surveillance. 
3. Study the non-invasive methods to quantify inflammation and fibrosis in 
autoimmune hepatitis.  
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Study I. The first study comprised patients derived from The Social Insurance 
Institution of Finland (SII) database. The patients collected had been granted 
special reimbursement for autoimmune hepatitis medication and had either an 
International Classification of Diseases and Related Health Problems volume 10 
(ICD-10) code K73.2 or K75.4 autoimmune hepatitis. This special reimbursement 
covers the costs of AIH medication for 70% of their original cost. Prior to approval, 
the certificate, written by a gastroenterologist or paediatrician, is checked by a 
medical examiner, pharmacist or a doctor at SII. 
All citizens of Finland have a personal identity code (PIC). With PICs, we could 
identify the patients from hospital discharge registries (HILMO) as well as the 
Finnish Cancer Registry, which contains data of causes of death and population 
averages for survival and causes of death. The PIC key also allowed us to cross 
reference the data with Statistics Finland to see the time of birth and death to 
calculate survival. Statistics Finland also provided us five sex-matched controls 
with the same birth year, same age and living in Finland at the index date October 
12th, 2016. The SII data from patients in the catchment area of Helsinki University 
Hospital was cross-checked with our own hospital’s registry to validate the data, 
and all these patients fulfilled the Simplified criteria for diagnosis of autoimmune 
hepatitis15. 
Patients were collected from 1995-2015, since we saw that ICD-10 (established in 
1995) was more valid than previous classifications, including both chronic active 
hepatitis (K73.2), which AIH was previously called, as well as autoimmune 
hepatitis (K75.4). There have been no changes in the special reimbursement 
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Study II. In the histological follow-up study, the patient population consists of 
patients who have had a liver biopsy in Helsinki University Hospital during 1995-
2012 with a diagnosis code of K73.2 or K75.4. In total, 193 patients had either 
K73.2 or K75.4. 123 of them fulfilled the 2008 Simplified criteria for the diagnosis 
of autoimmune hepatitis 15 for either probable or definite AIH. 20 patients were 
excluded due to a missing biopsy and three for positive viral hepatitis serology. 
Their diagnostic and follow-up biopsies were scored blindly by two experienced 
hepatopathologists. For inflammation and fibrosis, we used Metavir scoring 88. 
Altogether, we reviewed 241 liver biopsies from 100 patients. Two patients were 
excluded at histological analysis because there were no AIH features in the 
second analysis. 66 patients had at least one follow-up biopsy.  
We also had clinical, imaging and laboratory data from these patients. Remission 
was defined as the normalisation of immunoglobulin G and liver function test 
levels and the absence of interface inflammation in the liver biopsy. 
Study III. In the study where we tried to evaluate non-invasive monitoring of AIH, 
we recruited twelve patients in Helsinki University Hospital (HUH) with confirmed 
AIH diagnosis according to Simplified diagnostic criteria for diagnosis of 
autoimmune hepatitis. Requirements included established AIH diagnosis and a 
planned liver biopsy for follow-up of AIH. We used liver biopsy as the gold 
standard, while patients subsequently underwent Fibroscan (Echosens, France) 
transient elastography, standard liver function tests including immunoglobulin G 
and 31phosphorus magnetic resonance spectroscopy (31P MRS). Biopsy, blood 
samples, transient elastography, and 31P MRS were performed within a one-
month period, and before treatment was changed. 
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Study IV: Data for AIH prognosis after LT was gathered from the HUH 
Transplantation registry. HUH performs all liver transplantations in Finland. The 
first patient was transplanted due to AIH in 1992, and the data was collected until 
the end of 2012. We enrolled patients who fulfilled either probable or definite AIH 
diagnosis according to Simplified criteria for diagnosis of autoimmune hepatitis 15, 
resulting in 49 patients. Since we aimed to evaluate prognosis of AIH patients 
after LT, we included all these patients in the survival analysis. We have a biopsy 
surveillance protocol, and we take liver biopsies routinely at one and five years 
post-LT in AIH patients and every fifth year thereafter. Other primary endpoints 
were histological recurrence of AIH according to the Banff schema, and the effect 
of AIH recurrence on survival, and factors that contribute to AIH recurrence, 
fibrosis progression and cirrhosis development. We found 42 patients with follow-
up (protocol) biopsies taken after the first year of LT. Histological samples were 
blindly evaluated by two hepatopathologists.  Inflammation and fibrosis were 
graded according to the Metavir score 88, and acute and chronic rejection were 
graded according to the Banff Schema 115,116. AIH recurrence was diagnosed 
according to AIH diagnosis in a non-transplant setting, since there are no valid 
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Study I. The crude incidence and prevalence rates were calculated per 100,000 
person-years. The sex- and age-specific numbers were calculated according to 
Statistics Finland data. Kaplan-Meier curves were used to show survival rates. 
Cox regression was used for survival hazard ratios. 
The numbers of deaths and person-years at risk were counted by sex, age and 
years of follow-up. The expected numbers of all cause of death and for specific 
causes of death were calculated by multiplying the number of person-years in 
each stratum by the corresponding mortality rate in Finnish inhabitants. To 
calculate the standardised mortality ratio (SMR), the observed number of deaths 
was divided by the expected number. The 95% confidence intervals (CI) for the 
SMR assumed that the number of observed cases followed a Poisson distribution. 
Statistical computation was performed using the IBM SPSS Statistics version 24 
and R environment for statistical computing and graphics (R Development Core 
Team 2015) using the popEpi package. p<.05 was considered as statistically 
significant. 
Study II. In the biopsy follow-up, data was compared to primary data using 
Wilcoxon signed-ranks test for continuous parameters and McNemar’s test for 
binary and ordinal data. Ordinal and linear regression models were used in a 
multivariate model to find data that correlated with fibrosis advancement or 
cirrhosis development. The inflammatory load was calculated during the follow-up 
period integrating the semi-quantitative score over time to obtain the area under 
curve. Cohen’s kappa coefficient was used to calculate the correlation between 
histological and serological remission. SPSS v 22 (IBM corp, NY, USA), SAS 
(SAS institute, NC, USA) and Logexact v5 (Cytel corp, MA, USA) were used in 
statistical analysis. 
Study III. The data from the biopsy, transient elastography, laboratory 
tests, and 31P MRS were compared using the Pearson correlation coefficient for 
parametric tests and the Spearman rank correlation coefficient for nonparametric 
tests. A two-tailed T-test for unpaired samples was used to compare the means 
between groups. p<.05 was considered statistically significant. Statistical 
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analyses were performed with SPSS v 22 (IBM corp, NY, USA), SAS (SAS 
institute, NC, USA). 
Study IV. In the AIH after LT article, two groups with nominal values were 
compared with the Chi-square test to find correlations. Patient and graft survival 
were calculated with Kaplan-Meier analysis. The log-rank test was used with 
immunosuppressive treatment and survival. Spearman’s test was used between 
groups of patients with recurrent AIH and patients without. Cox regression was 
used in a univariate model to find risk factors for nominal parameters. All 
statistical analysis was done with the IBM SPSS version 22. p<.05 was 




Approval for the study was obtained from the Ethics committee of Internal 
medicine, Helsinki University Hospital (diary number 150/13/03/01/2012) and the 
Internal Medicine department. According to Finnish regulations, patient consent is 
not needed in registry studies. Written informed consent for study III was retrieved 
from the study subjects. 
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5.1 Study I. Epidemiology and causes of death 
 
The mean incidence of AIH in Finland was 1.1/100,000/year, 1.6/100,000/year in 
women and 0.52/100,000/year in men between 2008-2015, Fig 3. Age and sex-
specific incidences are shown in Figure 4. The prevalence of AIH in 2015 was 
14.3/100,000, 23.0/100,000 in women and 6.6/100,000 in men. The overall 
survival was lower in AIH patients compared to controls. The standardised 
mortality ratio (SMR) was 1.81 (95% CI 1.47-2.20), p<.001, 1.69 (95% CI 1.32-
2.14), p<.001 in women and 2.14 (95% CI 1.44-3.04), p<.001. SMR in age 0-29 
years was 6.69 (95% CI 1.38-19.55), p<.05, between ages 30-59 SMR was 2.08 
(95% CI 1.19-3.37), p<.05, and after 60 years SMR was 1.72 (95% CI 1.36-2.13), 
p<.001. Statistically significant causes for excess mortality in both sexes were 
hepatocellular carcinoma, cirrhosis, and autoimmune hepatitis. Diseases of the 
respiratory system as a cause of death were more common in women compared 
to the standard population, as were diseases of the circulatory system in men; 
However, not a single disease code was dominant in these disease groups.  
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Figure 3. Annual mean incidence of AIH in Finland, with permission, Study I  
 
 
Figure 4. Age- and sex-specific incidence of AIH, with permission, Study I 
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5.2 Study II. Baseline and follow-up liver biopsies 
 
At the time of diagnosis, only seven patients of 98 were cirrhotic (7.1 %), and 61 
had no fibrosis at baseline. Of all the patients, 34 had additional features of 
cholangitis, either PBC or PSC. 52 patients presented with additional autoimmune 
disorders. During follow-up, 36 patients reached serological remission (normal 
transaminases and immunoglobulin G).  
We had follow-up biopsies from 66 patients. Fibrosis progressed in 28 (42%), 
remained stable in 26 (39%) and resolved in 12 (18%). 29 (44%) were at 
histological remission at least once during follow-up. 9 patients (14%) developed 
cirrhosis. Surprisingly, serological and histological remission had only a poor 
correlation with kappa .171, p=.003. 
Risk factors in an ordinal regression model at diagnosis for fibrosis progression 
were: in baseline liver biopsy, rosette formation odds ratio (OR) 2.0 (95% CI 1.1-
7.1), p=.027, inflammation grade 1.7 (95% CI 1.7-1.8), p=.047, and necrosis 1.4 
(95% CI 1.0-2.0), p=.040. Alkaline phosphatase (ALP) above the upper normal 
limit at baseline had an OR 10.1 (95% CI 1.5-66.9), p=.020. The absence of 
cholangitis had a protective effect with OR 0.40 (95% CI 0.1-1.0), p=.044.  
During follow up, the cumulative ALP level had OR 24.0 (95% CI 2.7-214.6), 
p=.005 and cumulative inflammatory load (combined inflammation grade in follow-
up biopsies) had OR 1.8 (95% CI 1.0-3.2), p=.048 for fibrosis progression. If 
inflammation in the biopsies was constantly grade two or more in the Metavir 
scale, the hazard ratio (HR) for development of cirrhosis was 5.1, (95 % CI 1.6-
16.2), p<.005, and if interphase inflammation was constantly grade two or more, 
the HR was 6.1, (95 % CI 1.9-20.2), p<.005. 
Patients with immunoglobulin G and alkaline phosphatase constantly over the 
upper normal limit (>15.0 and 105, respectively) had HR of 6.4, (95 % CI 1.7-
23.9), p<.006 for cirrhosis development. 
Predictive factors for radiological or clinical cirrhosis development were calculated 
in a univariate model. Due to the low number of endpoints, it was not possible to 
construct multivariate analysis. Metavir fibrosis score of 3-4, p=.0001; cholestasis, 
p=.007; rosettes, p=.044; erythrocyte sedimentation rate, p=.012; albumin, 
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p=.046; and platelet count, p=.003 were the significant predicting parameters for 
cirrhosis development.  
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5.3 Study III. 31Phosporus Magnetic resonance spectroscopy in the follow 
up of AIH  
 
Magnetic resonance spectroscopy seems to be a new promising non-invasive 
method for follow-up of both inflammation and fibrosis progression. 
Phosphoenolpyruvate (PEP) correlated with the histological inflammation grade 
(r=.746, p=.005), and it separated patients with a Metavir grade 1-3 inflammation 
from grade 0 patients (t=3.781, p=.009). PEP levels >0.35 had a sensitivity of 
100% (95% CI 54.1-100%), specificity of 66.7% (95% CI 22.3-96.7%), positive 
predictive value (PPV) of 75% (95%CI 34.9-96.8%) and negative predictive value 
(NPV) of 100% (95%CI 39.8-100%) to differentiate active inflammation (G1-3) 
from none, Fig 5. 
The phosphomonoester to phosphodiester (PME/PDE) ratio and 
phosphoethanolamine to glyserophosphoethanolamine (PE/GPE) ratio correlated 
with the Metavir fibrosis score (r=.668, p=.018 and r=.604, p=.037, respectively. 
PE/PGE separated patients with Metavir 3-4 from Metavir 0-2 fibrosis (t=3.810, 
p=.003), Fig 6. Sensitivity of PE/GPE for differentiating fibrosis 3-4 from fibrosis 0-
2 was 100% (95%CI 39.8-100%), specificity 50% (95%CI 15.7-84.3%), PPV 50% 
(95%CI 15.7-84.3) and NPV 100% (95%CI 39.8-100%) with 0.5 cut-off. With a 
cut-off of 0.7, the values were 50% (95%CI 6.8-93.2%), 100% (95%CI 63.1-
100%), 100% (95%CI 15.8-100%) and 80% (95%CI 44.4-97.5%). 
The median liver stiffness measured with transient elastography (TE) was 6.1 
kilopascals, range 3.0-10.8. Compared to histology, TE overestimated fibrosis in 
four patients and underestimated in two. There was no statistical correlation with 





Autoimmune hepatitis: Epidemiology,                        Helsinki University Hospital 
prognosis and follow-up 
 
 
Figure 5. Phosphoenolpyruvate in three groups of inflammation. From Study III, 
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Figure 6. Phosphoenolate/glyserophosphoethanolamine ratio elevation is a sign 
of advanced fibrosis. From Study III, reproduced with permission from Taylor & 
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5.4 Study IV. Prognosis of autoimmune hepatitis after liver transplantation  
 
In the cohort of patients transplanted for AIH, follow-up or protocol biopsies were 
available from 42 patients. All patients were on low dose methylprednisolone, 
60% on cyclosporine and 40% on tacrolimus. 69% had either azathioprine or 
mycophenolate. During a median of five-year (range 1.0-17.9) follow-up, AIH 
recurred in the graft in 15/72 (36% of patients), figure 7. The median time to 
recurrence of AIH was 2.7 years (range 1.0-15.1). One patient developed Metavir 
stage 3 fibrosis and one cirrhosis due to AIH recurrence, but no patients or grafts 
were lost due to recurrent AIH. LFTs were normal on 3 (20%) with histological 
AIH recurrence in a protocol biopsy. During follow-up, five grafts were lost (2 
hepatic artery thromboses, primary graft dysfunction, biliary stricture formation, 
and vanishing bile duct syndrome). Three patients died (coronary artery disease, 
metastatic renal carcinoma, and metastasized hepatocellular carcinoma). None of 
the graft or patient losses were attributed to AIH recurrence.  
Cyclosporine and tacrolimus were equal in this setting, but the absence of an 
antimetabolite increased the risk of AIH recurrence 
Even though AIH recurrence had no impact on patient or graft survival, fibrosis 
progression was markedly accelerated in patients with AIH recurrence, Figure 8. 
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Figure 7. AIH recurrence over time after LT. From Study IV, reproduced with 
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Figure 8. Progression of fibrosis according to AIH recurrence. From Study IV, 
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While planning this manuscript, our primary goals were to report the 
epidemiological data of autoimmune hepatitis in Finland and evaluate different 
aspects of follow-up. We were able to assess incidence and prevalence of 
autoimmune hepatitis in Finland, as well as its impact on causes of death. We 
showed that histological and serological and inflammatory activity during follow-up 
impacts patients’ outcome regarding fibrosis progression and cirrhosis 
development. Also, magnetic resonance imaging seems to be a promising 
method to evaluate fibrosis and inflammation non-invasively. Recurrence of 
autoimmune hepatitis was documented, as well as its impact on patient and graft 
survival. 
 
6.1 Study I. Epidemiology and causes of death. 
 
We showed in Study I that the incidence of AIH has remained stable in Finland 
since 2008 being 1.1/100,000/year. This is similar to what has been previously 
reported 7,23,24,27-30,33. Female preponderance (76%), and prevalence of 
14.3/100,000 were also parallel to previous studies. A new finding was that 
incidence among women rose with age, Figure 4. Previous studies have shown a 
bimodal distribution or a stable incidence by age. It is important to recognise that 
incidence in women was highest in the age group of 75-84, and new cases of AIH 
even emerged in women over 85 years old. In men, there were no AIH patients 
diagnosed after the age of 85 years, and no rise in incidence by age was seen. In 
both sexes, the greatest portion of patients were 45-84 years old. The mean ten-
year survival was 84% and the twenty-year survival was 76 %. Survival was 
statistically significantly lower compared to controls. This highlights the 
importance of good quality of treatment and follow-up. Still, the survival of AIH 
patients in the present patients’ cohort was markedly better than previously 
published, 48% at twenty years 8, although this data covered only patients 
followed up in one non-transplant centre. Data on long term prognosis of AIH is 
limited. 
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The cohort in Study I was distinctively different from what has previously been 
published, since registries have traditionally covered only one hospital area. So 
far, there has been only one nation-wide register study concerning AIH, the one 
published in Denmark 7. We had two registries where we could cross-validate the 
data, the hospital discharge registry and the Social insurance institution (SII) 
registry. The former probably overestimates the data since the diagnosis has not 
been re-checked. However, if a patient is recorded in the SII registry, the 
diagnosis must have been made by a gastroenterologist or a paediatrician, the 
patient must be on immunosuppressive medication, and personnel in the SII have 
checked that the diagnosis has been made properly. This setting does not require 
that valid scoring systems have been used in the diagnostics, so we do not know 
whether these patients fulfil international diagnostic criteria for AIH. 
Causes of death registry maintained by Statistics in Finland 
(https://www.stat.fi/til/ksyyt/index_en.html) and the Finnish cancer registry have 
data of all causes of death in Finland. We demonstrated that standardised 
mortality (SMR) was elevated in the total AIH population and in both sexes and all 
age groups. The most common causes of excess mortality were hepatocellular 
carcinoma (HCC), AIH per se, and liver cirrhosis. Respiratory system disorders in 
women and circulatory system diseases in men were statistically more prevalent 
in AIH patients than in controls, but the number of specific diagnoses within these 
groups were too small to be statistically analysed. It is important to recognise that 
the excess mortality in AIH is usually caused by AIH and its complications, and 
we did not see any additional mortality caused by immunosuppressive treatment 
(extrahepatic malignancies or infections). Even though HCC is less common in 
AIH cirrhosis than in other aetiologies of cirrhosis 7,83,117,118, we should find 
prognostic markers or indices for HCC surveillance, since ultrasound follow-up in 
all cirrhotic AIH patients would not be cost-effective with annual incidence of 
0.2%: It has been shown, that even an annual incidence of 4.1 of HCC would 
result in a cost of year saved of US$112 993 119. 
We do not know whether doctors use revised 1999 or simplified 2008 criteria 
while writing the certificates but SII does not use these criteria. Most probably the 
certificates were written on more clinical grounds. It seems that most patients 
treated for AIH for a longer period indeed fill the diagnostic criteria since their 
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sensitivity is very good. We do not know whether liver biopsy was performed in all 
patients but supposedly prior to long term immunosuppressive treatment the 
biopsy has been taken in almost all if not from all patients. Also, we did not have 
data, whether patients had cirrhosis or not.  
The main cause of excess mortality in AIH in a nation-wide registry was HCC. In 
study II we followed 98 patients from Helsinki university hospital. In this cohort 
we did not find a single HCC in AIH patients. Only 7% had cirrhosis at the time of 
diagnosis, which is presumably the reason that we were unable to find HCCs in 
our patient cohort. The frequency of cirrhosis was much lower than the 
traditionally referred 30% 7,27, probably due to the well-functioning primary care 
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6.2 Study II. Role of the follow-up liver biopsies.  
 
We showed that follow-up liver biopsies provide important prognostic information 
in the decision-making process, whether that patient is developing cirrhosis or 
advanced fibrosis. Not surprisingly, the cumulative inflammatory load was a 
significant risk factor. The most important histological parameters during follow-up 
were total inflammation and interphase inflammation with grade two or more. 
To date, it is not clear what optimal strategy is to follow-up AIH patients. The 
current recommendation by AASLD and EASL is to aim to normalisation of 
transaminases and immunoglobulin G level 51,71. The basis for this 
recommendation is that elevated liver function tests are associated to poor 
outcome, progression to cirrhosis, and relapse after treatment discontinuation 
8,81,120,121. On the other hand, these recommendations advise taking a liver biopsy 
prior to treatment discontinuation, but there is limited or no data to support this. 
Liver biopsy is the gold standard for fibrosis and inflammation grading, but it has 
its limitations. It is usually safe, with a high success rate under ultrasound 
guidance and few complications 122. Even in the setting of specialized liver 
pathologist using a standardized and well-validated scoring system (Metavir) 
grading hepatitis c, there was a fair amount of disagreement when grading 
disease activity and necrosis between pathologists 123. However, agreement 
between pathologist was almost perfect with fibrosis. One sample of liver tissue 
taken with a 1-2 cm needle with a 1.2-1.8 mm diameter represents 1/50 000 of 
the total mass of the liver and we now that fibrosis and inflammation are not 
equally distributed in the liver 124. 
As liver biopsy is invasive, we tried to calculate surrogate markers using only 
laboratory tests. Patients with immunoglobulin G and alkaline phosphatase 
constantly over the upper normal limit (>15.0 and 105, respectively) had HR of 
6.4, (95 % CI 1.7-23.9), p=.006 for cirrhosis development. The number of patients 
developing cirrhosis was small (9 out of 98), which prohibited calculation of more 
complex models. 
Fibrosis progressed in 28 patients (42%). Surprisingly, cumulative logarithmic 
alkaline phosphatase (ALP) had an odds ratio (OR) 24.0 (95% CI 2.7–214.6), 
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p = .005 for progression of fibrosis. Constantly elevated ALP had an OR of 3.4 (95 
% CI 1.2-10.1), p=.026. We do not know why ALP would be a surrogate marker 
for fibrosis development: this is not explained by the concomitant AIH-PSC-
overlap features. In fact, we saw that cholangitis or granulomas had a protective 
role against fibrosis development, though statistically insignificant. Pericholangitis 
had an OR of 0.4 (95%CI 0.1-1.0), p=.0435 for fibrosis progression. Furthermore, 
no patients with features of cholangitis developed cirrhosis in the follow-up. Age 
or gender did not influence fibrosis progression or cirrhosis development. 
In total, 43.9% of patients were in histological remission at least at one time point 
during follow-up. It is not surprising that most patients had active inflammation, 
since most often liver biopsies have been taken due to clinical grounds, usually 
prior to treatment withdrawal or in case of inadequate treatment response. It 
seems that determining deep remission will also require liver biopsy in the future, 
since serological and histological remission demonstrated poor correlation with 
kappa .171, p = .003. 
The weakness of the study was, that biopsies were not taken routinely. It is 
plausible that patient who were biopsied, had more complex AIH that required 
more data on histological activity. On the other hand, we usually take the biopsy 
prior to treatment with-drawl resulting in the high number of histological 
remissions in this cohort.  
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6.3 Study III. 31Phosporus Magnetic resonance spectroscopy in the follow 
up of AIH. 
 
Study III evaluated 31Phosphorus magnetic resonance spectroscopy in AIH 
patients’ follow-up. This is the first time this method was used in this setting. Our 
study was a preliminary one of twelve non-cirrhotic patients with AIH showing 
promising results. Phosphoenolpyruvate (PEP), a link in hepatic gluconeogenesis, 
was elevated in patients with active inflammation. It is traditionally not linked to 
liver injury per se but seems to be a reliable surrogate marker of liver injury. It 
correlated with histological inflammation, and it was able to differentiate patients 
with active inflammation from patients in histological remission. To our 
knowledge, this finding is new regarding magnetic resonance spectroscopy and 
any liver disease.  
The phosphomonoester (cell membrane precursor) to phosphodiester (cell 
membrane degradation product) ratio (PME/PDE) correlated well with fibrosis 
level, and the phosphoethanolamine (part of PME peak) to 
glyserophosphoethanolamine (part of PDE peak) ratio was able to separate 
patients with advanced fibrosis from patients with no or mild fibrosis. Our primary 
hypothesis was that transient elastography (Fibroscan®) would be a good 
indicator of liver fibrosis, but unexpectedly it seemed to have no role in fibrosis 
evaluation in our patient cohort, with overestimating fibrosis in two patients 
(probably due to active inflammation) but surprisingly underestimating fibrosis in 
four patients. We thought that evaluation of fibrosis would be secondary to 
inflammation, since treatment decisions are usually based on whether 
inflammation is suppressed or not, but we were able to find a method to evaluate 
both of these important parameters. 
This study is promising, but the number of patients is so far too small to make 
definite assumptions on MRS. On the other hand, we are now more aware, which 
metabolic disturbances to expect in the spectroscopy of AIH patients. 
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6.4 Study IV. Prognosis of autoimmune hepatitis after liver transplantation 
 
In patients transplanted for autoimmune hepatitis, we have used low dose 
methylprednisolone in combination with a calcineurin inhibitor in addition to an 
antimetabolite (azathioprine or mycophenolate mofetil) when well tolerated, which 
was the case in 69%. In our cohort, AIH recurred histologically in 36% of patients 
in a median of five-year (range 1.0-17.9) follow-up, but the disease course was 
benign, and no grafts were lost due to recurrent AIH, Fig 7. One patient 
developed vanishing bile duct syndrome, probably a form of chronic rejection, but 
no chronic rejections were diagnosed according to Banff schema 116. We used 
histological assessment since there is no consensus on AIH recurrence after LT 
concerning aminotransferase levels or immunoglobulin G levels. 
The median time of AIH recurrence was 2.7 years from LT, but the range was 1.0-
15.1 years. We also showed that AIH patients have a similar prognosis (patient 
and graft survival rates at one, five and ten years were 94, 86, and 86 % and 91, 
77, and 74 %) after LT compared to other aetiologies. The five-year survival was 
also better than reported by the European Liver Transplantation Registry 102, 86 
% vs 73%. One patient developed cirrhosis, and one had Metavir 3 fibrosis due to 
recurrent AIH. Development of cirrhosis was rare in our material (only one patient) 
and there was no statistical association found concerning it, but AIH recurrence 
correlated with the progression of fibrosis. Even though AIH seems to be benign, 
it is still important to follow-up and to try preventing the progression of fibrosis. 
Cyclosporine and tacrolimus were equal in this setting, but the absence of an 
antimetabolite increased the risk of AIH recurrence.  
We have taken protocol biopsies in AIH patients at one year, five years and every 
five years thereafter after LT. The rationale for this is to try to find AIH recurrence 
and other significant liver disease at an early stage. It appeared that in three 
patients (20%) recurrent AIH was diagnosed while alanine and aspartate 
transaminases were within normal limits. We assume that finding patients with 
recurrent AIH at an earlier stage, gives us more time to adjust treatment prior to 
graft loss, even though we did not show that recurrent AIH has any effect on graft 
survival. 
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Previously, it has been shown that de novo or recurrent AIH after LT is more 
common in patients with AIH with features of PSC or PBC 125,126 than its pure 
form. Interestingly, in our material, features of cholangitis seemed to protect from 
AIH recurrence. This is still a difficult and complex subject since disease 
mechanisms and even diagnostic criteria within these diseases and their variant 
forms remain to be decided. Even though these are diseases, future studies are 
warranted for better understanding their disease mechanics and diagnostic 
methods.  
The European liver transplant registry report from 2010 102 raises concerns about 
AIH patients over the age of 50, and specifically their infection complications and 
excess infectious cause mortality. The overall five-year survival in AIH patients 
over fifty years old is only 61% after LT 102.  In our cohort, one patient aged over 
fifty (out of 17) died of infectious complications in the post-operative period, 
showing that with proper patient selection, LT is safe for AIH patients aged over 
fifty.  
We strongly recommend triple immunosuppression after LT due to AIH to prevent 
AIH recurrence. Our study shows that AIH recurrence is relatively common after 
LT but has very little impact on graft or patient survival at least in the median of 5
year follow up.  
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7. Conclusions and future directions 
 
The main findings and future questions are: 
1. Prevalence of AIH has remained stable in the last years. Prevalence in a 
nation-wide cohort is comparable to previous reports from secondary and 
tertiary centres. Female preponderance is marked, and we show that 
especially in women, AIH occurs in all ages and often in the elderly. 
Hepatocellular carcinoma is rare but statistically the most important cause 
of excess death. Future studies are needed to recognise high-risk patients 
for hepatocellular cancer in order to target HCC surveillance in a cost-
effective manner. 
2. Liver biopsies might play a role in the follow-up of AIH, but to date, there 
are no good prognostic models to encompass liver histology therein. 
Ongoing histological inflammation is a risk factor for fibrosis progression 
and development of cirrhosis. Better non-invasive surrogate markers for 
disease progression and remission are needed as well as prognostic 
models and discussion concerning histological follow-up. 
3. 31Phosporus magnetic resonance imaging of the liver is a promising follow-
up tool and is acceptable to patients. These preliminary results should be 
confirmed in larger studies. Transient elastography was not useful in this 
setting. 
4. AIH recurs after liver transplantation in 36% of patients, but its disease 
course is primarily benign. Triple immunosuppression (minimal dose 
corticosteroid, calcineurin inhibitor and antimetabolite) is advisable after LT 
when tolerable. We encourage protocol biopsies after LT due to 
autoimmune hepatitis liver diseases to find patients with recurrent AIH at 
an earlier stage. 
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Finnish and Swedish summaries 
 
Autoimmuunimaksatulehdus: Epidemiologia, ennuste ja seuranta 
Autoimmuunimaksatulehdus on pitkäaikainen tulehduksellinen maksasairaus, 
jolle on tunnusomaista interfaasialueen maksasoluihin kohdistuva tulehdus 
koepalatutkimuksessa, koholla oleva veren kokonaisvasta-ainetaso ja verestä 
mitattavat ihmisen omaan elimistöön kohdistuvat vasta-aineet. 
Autoimmuunimaksatulehduksen syy on useimmiten epäselvä, mutta yhdistelmä 
ympäristöriskeistä, puolustusjärjestelmän poikkeava tapa reagoida vieraisiin 
aineisiin ja perintötekijöistä johtuva elimistön puolustussolujen herkkyys reagoida 
maksan solujen proteiineihin. Tämä johtaa maksasolukuolemaan ja -
tulehdukseen ja lopulta sidekudoksen muodostumiseen. 
Autoimmuunimaksatulehduksen ilmaantuvuus ja esiintyvyys nousevat. 
Osoitimme, että autoimmuunimaksatulehduksen mediaani ilmaantuvuus 1995-
2005 oli 0,9/100 000/vuosi; 1,2/100 000/vuosi naisilla ja miehillä 0,38/100 000 
/vuosi. Kasvua oli 0,28/100 000 - 1,04/100 000 tutkimusaikana. Esiintyvyys 
vuonna 2015 oli 14,3/100 000; 23,0/100 000 naisilla ja 6,6/100 000 miehillä. 
Standardoidun kuolleisuuden suhde oli muuta väestöä korkeampi kaikissa 
ikäryhmissä ja molemmilla sukupuolilla. Yleisimmät ylimääräisen kuolleisuuden 
syyt olivat maksasolusyöpä, maksakirroosi ja autoimmuunimaksatulehdus 
sinänsä. 
Maksakudosnäyte tarvitaan autoimmuunimaksatulehduksen alkuvaiheessa, jotta 
voidaan varmistaa diagnoosi, ja toisaalta koepalalöydöksillä tiedetään olevan 
ennusteellisia merkityksiä. Rutiininomainen kudosnäyteseuranta sen sijaan on 
kiistanalainen. Helsingissä olemme ottaneet rutiininomaisesti seurantakoepaloja 
ja arvioimme niiden vaikutusta hoitovaihtoehtoihin ja ennusteeseen. Löysimme 
ennusteellisia muuttujia sidekudoslisän ja kirroosin kehittymiseen 
seurantakoepaloissa: interfaasialueen maksasoluihin kohdistuva tulehdus tai 
kokonaistulehdus, solutuho, sappikertymä tai rosetit alkuvaiheen koepalassa 
ennustivat sidekudoksen kehittymisetä. Jos seurantakoepaloissa tulehdus oli 
jatkuvasti vähintään keskivaikea, kirroosin riskitiheyssuhde oli 5.1 (95 % 
luottamusväli 1.6-16.2), p <.005 ja jos interfaasialueen maksasoluihin kohdistuva 
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tulehdus oli jatkuvasti vähintään kaksi, riskitiheyssuhde oli 6.1 (95 % 
luottamusväli 1.9-20.2), p <0,005. Vain seitsemällä prosentilla potilaista oli 
kirroosi lähtötilanteessa. Sidekudosmäärä eteni 42 prosentilla potilaista, pysyi 
vakaana 39 prosentilla ja väheni 18 prosentilla. 
HUS Kuvantamisessa on tutkittu magneettiresonanssispektroskopiaa 3 Teslan 
kuvantamislaitteella rasvamaksa- ja hepatiitti c -potilailla. Elastografia 
(Fibroscan®) on ultraäänipohjainen tekniikka, joka mittaa maksan jäykkyyttä, 
jonka ajatellaan liittyvän sidekudoksen määrään. Elastografia voi erottaa pitkälle 
edenneen sidekudoksen ja kirroosin normaalista maksasta. Se ei kuitenkaan 
mittaa tulehduksen määrää. Uusia kajoamattomia testejä tarvitaan tulehduksen ja 
sidekudoksen arvioinnissa, joten vertasimme maksan kudosnäytettä, veriarvoja, 
elastografiaa ja magneettiresonanssispektroskopiaa toisiinsa. 
Magneettiresonanssispektroskopia löysi erilaisen maksasolujen 
aineenvaihduntatuotteiden kirjon potilailla, joilla oli kehittynyt sidekudoslisä tai 
aktiivinen tulehdus verrattuna maksan Koepalaan. Elastografia ei toiminut 
sidekudoksen arvioinnissa verrattuna koepalalöydökseen. 
Autoimmuunimaksatulehdus on vakiintunut maksansiirtoaihe, kun potilaalla on 
maksakirroosi, huono maksan toiminta, vaikeat maksasairauden oireet tai 
maksasolusyöpä. Helsingin yliopistollisessa sairaalassa on kattava rekisteri 
maksansiirron saaneista autoimmuunimaksatulehduspotilaista ja olemme 
keränneet säännölliset protokollakudosnäytteet maksansiirron jälkeen. Vuosina 
1982-2012 tehtiin 42 maksansiirtoa autoimmuunimaksatulehduksen takia. 
Autoimmuunimaksatulehdus uusi 36%:lla potilaista siirron jälkeen ja 
keskimääräinen aika uusiutumiseen oli viisi vuotta (vaihteluväli 1,1-15,1). Uusiva 
autoimmuunimaksatulehdus ei vaikuttanut potilaan tai siirteen ennusteeseen. 
Potilaan ja siirteen ennuste oli 94% ja 86% yhden vuoden, 86% ja 91% viiden 
vuoden, ja 77% ja 74% kymmenen vuoden aikana. Hyljinnänestolääkitys 
kortisonin ja kalsiuneuriini-inhibiittorin yhdistelmä ilman atsatiopriinia tai 
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Autoimmun hepatit: Epidemiologi, prognos och uppföljning 
 
Autoimmun hepatit är en kronisk inflammatorisk leversjukdom, som kännetecknas 
av interfas hepatit på histologisk undersökning, hypergammaglobulinemi och 
autoantikroppar mätt från blodet. Etiologi av autoimmun hepatit är mestadels 
oklar, men en triad av miljötriggers, misslyckande i immunförsvarets tolerans och 
känslighet på grund av genetiska faktorer inducerar en T-cellmedierad 
immunattack mot antigener i levern som leder till nekroinflammatorisk 
hepatocytskada och fibros generation. Incidensen och prevalensen av AIH antas 
vara lika med det av primär biliar kolangit och dubbla mängden primär 
skleroserande kolangit. Epidemiologiska data av autoimmun hepatit är sällsynta, 
och samlas ofta in från ett enda centrum. Incidensen och prevalensen av 
autoimmun hepatit ökar. AIH åtföljs också ofta av andra autoimmuna sjukdomar. 
Vi visade att incidensen av median autoimmun hepatit mellan 1995 och 2015 var 
0,9/100 000/år, 1,2/100 000/år hos kvinnor och 0,38/100 000/år hos män, och den 
gick från 0,28/100 000 till 1,04/100 000 under studieperioden. År 2015 var 
förekomsten av autoimmun hepatit 14,3/100 000, 23,0/100 000 hos kvinnor och 
6,6/100 000 hos män. Det standardiserade dödlighetstalet ökade i alla 
åldersgrupper och i båda könen. De mest vanligast förekommande orsakerna till 
dödlighet jämfört med standardpopulationen var levercancer, cirros och 
autoimmun hepatit i sig. 
Leverhistologi behövs vid autoimmun hepatit diagnos för att fastställa diagnos, 
och histologiska fynd är kända för att vara av prognostisk betydelse. Implikationen 
av rutinmässig uppföljning med biopsier är mer kontroversiell. I Helsingfors har vi 
rutinmässigt tagit leverbiopsiprover och bedömt deras inverkan på behandling och 
prognos. Vi kunde utvärdera prognostiska variabler för att främja fibros eller cirros 
genom att följa upp biopsierna: Interfas eller total inflammation, nekros, kolestas 
eller rosettbildning vid baslinjebiopsi. Om inflammationen vid uppföljningen av 
biopsierna ständigt var grad två eller mer på en METAVIR-skala, var 
riskförhållandet för cirros 5.1 (95 % konfidensintervall 1.6-16.2), p <.005, och om 
interfas inflammation var konstant grad två eller mer, var riskförhållandet 6.1 (95 
% konfidensintervall 1.9-20.2), p <.005. Endast sju procent av patienterna var 
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cirrotiska vid baslinjen. Fibrosis fortskred hos 42 % av patienterna, förblev stabil 
hos 39 % och minskade hos 18 %. 
Vid Helsingfors universitetssjukhus Bilddiagnostik har dessutom 
magnetresonans-spektroskopi med 3 Tesla modalitet använts vid icke-
alkoholhaltiga fettlever och hepatit C. Elastografi (Fibroscan ®) är en 
ultraljudsbaserad teknik som bedömer fibros vid leversjukdom. Elastografi kan 
särskilja avancerad fibros och cirros från normal leverhistologi men är inte 
användbart vid lindrig fibros. Dessutom spelar det ingen roll vid utvärderingen av 
inflammation. Nya icke-invasiva tester vid utvärdering av inflammation och fibros 
behövs, och vi jämförde leverhistologi med leverfunktionstest, elastografi och 
magnetisk resonansspektroskopi. Magnetisk resonansspektroskopi visade olika 
nyckeltal för utvalda hepatocytförändringar i metaboliter hos patienter med 
avancerad fibros eller aktiv inflammation hos tolv på varandra följande 
autoimmuna hepatitpatienter jämfört med leverhistologi. Elastografi var 
verkningslös vid kvantifiering av fibros. 
Autoimmun hepatit är en väl etablerad indikation för levertransplantation hos 
cirrotiska patienter med obehandlade symtom på portal hypertoni, dålig 
leverfunktion, allmänna symtom eller levercancer. Vid Helsingfors 
universitetssjukhus har vi ett omfattande register över levertransplanterade AIH-
patienter och vi har regelbundet fört protokoll över biopsier efter transplantation. 
Under åren 1982–2012 gjordes 42 levertransplantationer på grund av autoimmun 
hepatit. Autoimmun hepatit recidiverade hos 36 % av patienterna och 
mediantiden till recidiv var fem år (intervall 1.1–15.1). Recidiv autoimmun hepatit 
påverkade inte patientens eller transplantationens överlevnad. Patientens och 
transplantationens prognos var 94 % och 86 % efter ett år, 86 % och 91 % efter 
fem år, och 77 % och 74 % efter tio år. Immunosuppression utan en antimetabolit 
ökade risken för autoimmun hepatit recidiv. 
